A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 401 participants.
Also called NCT06010004
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 401 participants
- Sponsor
- Registry
-
NCT06010004
-
- Other papers using this trial's data
- Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT06010004. Randomized; no masking; primary purpose treatment. Start 2023-09-28 (actual); primary completion 2025-06-05 (actual). Results posted on 2026-06-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
- Acronym
- ACHIEVE-J
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Orforglipron
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct06010004- Content hash
fa82f62bcb241442d451db5889d8fa99dd2200351be567c1d13ea740b85499c0